Table 4.

Risk of Adenoma According to Celecoxib Treatment, Stratified by Aspirin Use and UGT1A6.³⁶

	Placebo	Celecoxib 200 mg twice daily	Celecoxib 400 mg twice daily
All genotypes
All patients, no. at risk	493	497	494
Cumulative incidence, 3 y, % ±SE	59.8 ± 2.3	43.3 ± 2.3	36.8 ± 2.3
RR (95% CI)	1.0	0.66 (0.59-0.79)	0.54 (0.46-0.64)
P value	—	<.001	<.001
Aspirin users, no. at risk	162	160	152
Cumulative incidence, 3 y, % ±SE	61.0 ± 4.0	46.0 ± 4.1	38.7 ± 4.1
RR (95% CI)	1.0	0.69 (0.54-0.89)	0.54 (0.41-0.73)
P value	—	.004	<.001
Non-aspirin users, no. at risk	331	337	342
Cumulative incidence, 3 y, % ±SE	59.2 ± 2.8	42.0 ± 3.5	36+2.7
RR (95% CI)	1.0	0.67 (0.56-0.81)	0.54 (0.44-0.66)
P value	—	<.001	<.001
Patients with wild-type genotypes
All wild-type genotypes, no. at risk	212	213	221
Cumulative incidence, 3 y, % ±SE	62.3 ± 3.4	42+3.5	36.3 ± 3.4
RR (95% CI)	1.0	0.63 (0.50-0.78)	0.51 (0.40-0.65)
P value	—	<.001	<.001
Aspirin users, no. at risk	74	69	69
Cumulative incidence, 3 y, % ±SE	64.3 ± 3.4	44 ± 6.2	35.7 ± 6.1
RR (95% CI)	1.0	0.64 (0.44-0.92)	0.51 (0.33-0.77)
P value	—	.013	<.001
Non-aspirin users no. at risk	138	144	152
Cumulative incidence, 3 y,% ±SE	61.4 ± 4.2	41 ± 4.3	36.5 ± 4
RR (95% CI)	1.0	0.62 (0.47-0.82)	0.51 (0.38-0.69)
P value	—	<.001	<.001
Patients with variant genotypes
All variant genotypes, no. at risk	281	284	273
Cumulative incidence, 3 y,% ±SE	57.9 ± 3.1	44.2 ± 3.1	37.1 ± 3
RR (95% CI)	1.0	0.72 (0.59-0.88)	0.57 (0.45-0.71)
P value	—	.001	<.001
Aspirin users, no. at risk	88	91	83
Cumulative incidence	58.4 ± 5.4	47.4 ± 5.1	40.7 ± 5.6
RR (95% CI)	1.0	0.74 (0.53-1.04)	0.57 (0.38-0.86)
P value	—	.084	.005
Non-aspirin users, no. at risk	193	193	190
Cumulative incidence	57.6 ± 3.7	42.6 ± 3.7	35.6 ± 3.6
RR (95% CI)	1.0	0.71 (0.56-0.91)	0.56 (0.44-0.73)
P value	—	.006	<.001

Note. RR = relative risk; CI = confidence interval.